Try our beta test site
3 studies found for:    Ambrisentan and Tadalafil | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
Condition: Hypertension, Pulmonary
Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose;   Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)
2 Not yet recruiting Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Oral Treprostinil;   Drug: Placebo
3 Recruiting Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH
Condition: Pulmonary Arterial Hypertension
Intervention: Other: no intervention, only observation of different groups

Study has passed its completion date and status has not been verified in more than two years.